FDA Recall: Baxter Cefazolin in Dextrose Injection
Source: FDA
File Your Claim Now

FDA Recall: Baxter Cefazolin in Dextrose Injection

Baxter • July 24, 2026

Baxter Cefazolin Injection Recall: FDA Warns of Cardboard Particles (Lot LD175708)

Immediate action required. Baxter International Inc. has issued a nationwide recall for one lot of Cefazolin in Dextrose Injection, USP 2 g/100 mL after cardboard fragments were discovered in the solution. Infusing contaminated bags may lead to serious bloodstream complications. Healthcare professionals should stop use and quarantine the product at once.

Recall Quick Facts

  • Product: Cefazolin in Dextrose Injection, USP 2 g/100 mL (20 mg/mL) single-dose infusion bag
  • Company: Baxter International Inc.
  • Reason: Visible cardboard particulate contamination
  • Affected Lot: LD175708  |  Expiration: 14-Feb-2027
  • NDC: 0338-3508-41  |  Product Code: 2G3508
  • Distribution Dates: 03/25/2025 – 06/30/2025 (U.S.)
  • FDA Recall Report Date: 24-Jul-2026

Primary Source

Why the Baxter Cefazolin Recall Is Critical

Intravenous administration of foreign particles can obstruct blood vessels, trigger phlebitis, and cause pulmonary embolism or organ damage. While no injuries have been reported, the FDA states that continued use poses a reasonable probability of serious adverse events; therefore, the lot must be removed from circulation.

Required Actions for Healthcare Facilities

  1. Locate and isolate any Lot LD175708 infusion bags (check both outer carton and bag label).
  2. Stop using the product immediately and place it in a segregated quarantine area.
  3. Initiate your facility’s return process; Baxter will provide detailed return instructions.
  4. For questions, contact Baxter Healthcare Center for Service at 888-229-0001 (Mon – Fri, 7 a.m.– 6 p.m. CT).
  5. Report any adverse events to the FDA MedWatch program:

Recall Images

Baxter Cefazolin IV bag with lot number LD175708 highlighted
Source: FDA
Close-up of Baxter Cefazolin IV bag showing lot LD175708 details
Source: FDA
Baxter Cefazolin carton with lot LD175708 and expiry date
Source: FDA

Frequently Asked Questions

Which Baxter Cefazolin in Dextrose Injection lot is under recall?

The recall affects only Lot LD175708 of Baxter’s Cefazolin in Dextrose Injection, USP 2 g/100 mL, packaged in 100 mL GALAXY plastic containers.

Why did Baxter recall Cefazolin in Dextrose Injection Lot LD175708?

Quality testing revealed visible cardboard particles in the IV solution, creating a risk of vascular blockage and other serious complications if infused.

What health risks can Baxter Cefazolin particulate contamination cause?

Infused particles may lead to pulmonary embolism, phlebitis, blood vessel occlusion, systemic immune responses, organ dysfunction, or hemolysis.

How should hospitals handle the recalled Baxter Cefazolin bags?

Immediately discontinue use, quarantine the affected stock, follow Baxter’s return instructions, and document the action per facility policy.

Will Baxter replace the recalled Cefazolin in Dextrose Injection products?

Baxter typically offers credit or replacement upon receipt of the returned product. Contact Baxter Healthcare Center for Service for specific guidance.

How can clinicians report adverse reactions linked to Baxter Cefazolin Lot LD175708?

Report incidents to FDA MedWatch online or via the downloadable form, and notify Baxter’s customer service to assist with investigation.

Content current as of 24-Jul-2026. This article summarizes information released by Baxter International Inc. and the U.S. FDA; no new therapeutic claims are made.

File Your Claim Now